The Week in Review: March 2 – March 9, 2018

Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...

Tenofovir disoproxil fumarate (TDF) not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives

Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen — administration of hepatitis B vaccine and prote

Managing HBV Infection Following Liver Transplant: Expert Q&A

Prior to the introduction of effective prophylactic therapy, liver transplantation in patients infected with hepatitis B virus (HBV) resulted in high rates of viral recurrence, allograft loss, and mortality.  One retrospective study found the risk of HBV recurrence to be as high as 75% in liver transplant patients who were not given immunoprophylaxis.  Therapeutic advances in the past 2 decades have drastically changed the outlook for patients infected wi

The Week in Review: February 23 – March 2, 2018

Friday, March 2, 2018 News Recap: Canada: Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease. Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4. Ontario Expands Patient Acce...

Chronic Hepatitis B: Serum ALT Cutoff Value Predictive of Liver-Related Mortality

In patients with chronic hepatitis B, serum alanine aminotransferase (ALT) levels are positively correlated with liver-related mortality, according to study results published in Liver International. The researchers recommend that patients age >40 with serum ALT levels above the upper limit of normal should be carefully monitored or started on antiviral therapy earlier. Read more...

The Week in Review: February 9 – February 16, 2018

Friday, February 16, 2018 News Recap: HCV & Heart Disease: Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD. This article examines the evidence for clinical and subclinical cardiovascular diseases in chronic hepatitis c infection, as well as the effect of treatment on cardiovascular outcomes. News from Around the World: NZ: Thousands of Hepatitis C sufferers unaware a cure is within reach. A Hepatitis...

Study reveals the liver’s ‘weak spot’ for hepatitis B virus replication

In a surprising discovery, researchers from the Singapore Immunology Network (SIgN), A*STAR, have found that the liver is the main site of hepatitis B (HBV) replication—not only because it contains material that helps the virus proliferate, but also because most other tissues of the body contain proteins that actively repress HBV replication. "We've been working on this project for a number of years because HBV is very prevalent in Asia," says Ee Chee Ren

The Week in Review: February 2 – February 9, 2018

Friday, February 9, 2018 News Recap: Epidemiology: CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. #EASLmono: Expanding the conversation on hepatitis elimination. The recent European...

7 recent reports on HBV treatment approvals, efficacy

Direct-acting antivirals have provided a highly viable cure for hepatitis C, but hepatitis B remains a complicated infectious disease and requires lengthy treatment and management in chronic cases. While HBV is vaccine-preventable, individuals who do contract HBV must be aware of its progression as it can lead to severe liver-related complications such as acute liver failure and may require liver transplantation. The following reports provide recent findi

GeoVax and CaroGen to Collaborate On Development of Therapeutic Hepatitis B Vaccine

Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide. ATLANTA, GA, Feb. 07, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with CaroGen Corporation on the development of a combination immunotherapy treatment for chronic hepatitis B virus (HBV) infection. The project will include testing GeoVax’s MVA-VLP-HBV (Modified